In addition, it does not allow guidewire placement. PD0332991 cost Further developments by using this model are required. Nevertheless, it is possible to teach alignment of the sphincterotome with the papilla for sphincterotomy and papillectomy. In addition, stabilization of the duodenoscope and sphincterotome, direction and speed of cutting, adjustment of sphincterotome tension, aspects of needle-knife handling, and proper use of a snare can all be practiced in this model. Although further studies are necessary to evaluate its reproducibility and cost-effectiveness compared with other models such as the

Erlangen model,5, 6 and 8 this novel pig model appears useful for ES and EP training. Whether the same results could be achieved by using a fresh animal stomach mounted on a tray (compact EASIE)7 needs to be evaluated. A standard training program by using this animal model needs to be developed and validated for it to enhance the learning curve BGB324 mw and improve patient safety. The authors are indebted to Professor J. Patrick Barron, Chairman of the Department of International Medical Communications of Tokyo Medical University, for his editorial review of this manuscript. “
“Topical hemostatic agents:

Topical hemostatic agents in endoscopists’ armamentarium include Ankaferd Blood Stopper, TC-325 (Hemospray), and Endoclot. Mechanism of action: The Ankaferd Blood stopper, not TC-325, is a topical hemostatic agent that promotes the formation of a protein lattice, which facilitates the aggregation of erythrocytes and the clotting cascade.1 TC-325 and EndoClot work by absorbing the fluid component of blood, which concentrates platelets, red cells, and coagulation proteins at bleeding sites and accelerates clot formation. The TC-325 compound forms an adherent and cohesive

barrier when exposed to moisture that sloughs off after 24 to 72 hours rather than a period of months.2 Endoscopic delivery of TC-325: TC-325, which is delivered using a carbon dioxide pressurized spray catheter, is likely to be a favorable treatment for tumor bleeding given its ability to cover a large surface area and simultaneously almost treat multiple sites of bleeding with minimal tissue injury.3 The manufacturer of TC-325 recommends against endovascular use given the potential risk of thromboembolism. Clinical trials of TC-325 have thus far excluded patients with variceal bleeding, although it has been successfully sprayed on but not injected into gastric varices in reported cases.4 Take-home point: Think about topical hemostatic agents in patients with massive bleeding, bleeding that fails to respond to conventional therapies, and bleeding GI malignancies. 1 Turhan N, Kurt M, Shorbagi A, et al. Topical Ankaferd Blood Stopper administration to bleeding gastrointestinal carcinomas decreases tumor vascularization. Am J Gastroenterol 2009;104:2874-7.